Search - tctmd.com

Displaying 201 - 220 of 1340

Sort: Relevancy | Date

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presentation TCT 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presenter: Johny Nicolas

September 17, 2022

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

Presentation TCT 2022

TCT 2: Two-Year Outcomes in High Bleeding Risk Patients with Bifurcations after Percutaneous Coronary Intervention and One Month Dual Antiplatelet Therapy

Presenter: Ajay Kirtane

September 17, 2022

Presentation TCT 2022

TCT 15: Dual antiplatelet therapy-based de-escalation in acute coronary syndrome: An individual patient data meta-analysis

Presenter: Jeehoon Kang

September 17, 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presentation TCT 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presenter: Giulia Masiero

September 17, 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presentation TCT 2022

TCT 21: Preferred Strategy in the Era of Short-Term Dual Antiplatelet Therapy: A Systematic Review and Network Meta-Analysis of Randomized Trials

Presenter: Toshiki Kuno

September 17, 2022

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

News Daily News

Late Bleeding Not Rare, Ups Mortality After TAVI in All-Asian Cohort: OCEAN-TAVI

Yael L. Maxwell

September 08, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Watchman FLX Gets DAPT Option Added to Label

News Daily News

Watchman FLX Gets DAPT Option Added to Label

September 06, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

News Conference News ESC 2022

Higher BP, Oxygen Targets No Help in Comatose OHCA Patients: BOX

August 27, 2022

Steep Rise in PVAD Support for Protected PCI: Medicare Data

News Daily News

Steep Rise in PVAD Support for Protected PCI: Medicare Data

August 19, 2022

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

News Daily News

Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes

July 28, 2022

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

July 20, 2022

Triggers for Palliative Care in Advanced HF: Many Opportunities

News Daily News

Triggers for Palliative Care in Advanced HF: Many Opportunities

July 18, 2022

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

June 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.